TABLE 2.
Demographic and clinical data in patients under entecavir or lamivudine treatment before bilirubin level reached >15 mg/dl
| Parameter | Value for group |
P | |
|---|---|---|---|
| Entecavir (n = 50) | Lamivudine (n = 100) | ||
| Age (yrs)a | 49 ± 13 | 42 ± 14 | 0.002 |
| Sex (M/Fb) | 36/14 | 78/22 | 0.424 |
| AST (U/liter)a | 809 ± 667 | 1,037 ± 1,024 | 0.156 |
| ALT (U/liter)a | 1,258 ± 741 | 1,629 ± 1,021 | 0.023 |
| Albumin (g/dl)a | 3.7 ± 0.6 | 3.5 ± 0.6 | 0.144 |
| Bilirubin (mg/dl)a | 5.7 ± 3.7 | 6.4 ± 3.8 | 0.273 |
| Creatinine (mg/dl)a | 0.9 ± 0.2 | 0.9 ± 0.2 | 0.480 |
| Prothrombin time (INR)a | 1.3 ± 0.3 | 1.4 ± 0.3 | 0.393 |
| Platelet (cells x 109 /ml)a | 157 ± 59 | 174 ± 60 | 0.081 |
| HBeAg (positive/negative) | 15/35 | 43/57 | 0.086 |
| HBV DNA (×105copies/ml)a | 1,507 ± 348 | 1,770 ± 478 | 0.741 |
| Mortality | 5/50 (10%) | 3/100 (3%) | 0.082 |
a
Data presented as means ± standard deviations.
b
M, male; F, female.